Haloperidol increases prolactin release and cyclic AMP formation in vitro: inverse agonism at dopamine D2 receptors?

J Neural Transm Gen Sect. 1993;92(2-3):213-20. doi: 10.1007/BF01244880.

Abstract

Haloperidol (30 nM, 3 microM) was found to increase prolactin release from GH4C 1 cells transfected with the D2 receptor cDNA (GH4ZR 7) and from wild-type (untransfected) GH 3 cells, but not from wild-type GH4C 1 cells. In addition, haloperidol (3 microM) stimulated cAMP formation in GH 3 cells. It is suggested that haloperidol may act as an inverse agonist rather than as a neutral antagonist at dopaminergic D2 receptors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-Methyl-3-isobutylxanthine / pharmacology
  • Animals
  • Cell Line
  • Cyclic AMP / biosynthesis*
  • Dopamine Agents / pharmacology*
  • Haloperidol / pharmacology*
  • Prolactin / metabolism*
  • Radioimmunoassay
  • Rats
  • Receptors, Dopamine D2 / drug effects*
  • Receptors, Dopamine D2 / genetics
  • Receptors, Dopamine D2 / metabolism
  • Vasoactive Intestinal Peptide / pharmacology

Substances

  • Dopamine Agents
  • Receptors, Dopamine D2
  • Vasoactive Intestinal Peptide
  • Prolactin
  • Cyclic AMP
  • Haloperidol
  • 1-Methyl-3-isobutylxanthine